Summary
Lacosamide is a new chemical entity being investigated as an adjunctive treatment for epilepsy, as well as monotherapy for diabetic neuropathic pain. Lacosamide appears to have a dual mode of action: selective enhancement of sodium channel inactivation and modulation of collapsin response mediator protein-2. Rapidly and completely absorbed after oral administration, lacosamide has an elimination half-life of approximately 13 hours and a low potential for drug interactions. Additionally, lacosamide exhibits linear, dose-proportional pharmacokinetics with low intra- and interpatient variability. Randomized controlled trials of adjunctive lacosamide (200, 400, and 600 mg/day) have demonstrated statistically significant reduction in median seizure frequency compared with placebo. In addition, 50% responder rates for lacosamide (400 and 600 mg/day) were statistically superior to placebo. The most frequently reported adverse events (≥10% of lacosamide-treated patients) included dizziness, headache, and nausea. A double-blind, double-dummy randomized trial of intravenous lacosamide (30- and 60-minute infusion) as replacement for oral lacosamide showed that the safety and tolerability profiles were comparable for intravenous and oral lacosamide. The efficacy and safety results from completed clinical trials, as well as the favorable pharmacokinetic profile, suggest that lacosamide may represent a significant advance in antiepileptic drug therapy.
Key Words: Lacosamide, antiepileptic drugs, anticonvulsants, epilepsy, partial-onset seizures
References
- 1.Andurkar SV, Stables JP, Kohn H. The anticonvulsant activities ofN-benzyl 3-methoxypropionamides. Bioorg Med Chem. 1999;7:2381–2389. doi: 10.1016/S0968-0896(99)00186-8. [DOI] [PubMed] [Google Scholar]
- 2.Duncan GE, Kohn H. The novel antiepileptic drug lacosamide blocks behavioral and brain metabolic manifestations of seizure activity in the 6 Hz psychomotor seizure model. Epilepsy Res. 2005;67:81–87. doi: 10.1016/j.eplepsyres.2005.08.009. [DOI] [PubMed] [Google Scholar]
- 3.Hovinga CA. SPM-927 (Schwarz Pharma) IDrugs. 2003;6:479–485. [PubMed] [Google Scholar]
- 4.Stohr T, Stables JP, Wilcox K, White HS. The pre-clinical profile of the novel anticonvulsant lacosamide. Epilepsia. 2005;46(suppl 6):373–373. [Google Scholar]
- 5.LeTiran A, Stables JP, Kohn H. Functionalized amino acid anti-convulsants: synthesis and pharmacological evaluation of conformationally restricted analogues. Bioorg Med Chem. 2001;9:2693–2708. doi: 10.1016/S0968-0896(01)00204-8. [DOI] [PubMed] [Google Scholar]
- 6.Brandt C, Heile A, Potschka H, Stoehr T, Löscher W. Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia. 2006;47:1803–1809. doi: 10.1111/j.1528-1167.2006.00818.x. [DOI] [PubMed] [Google Scholar]
- 7.Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V) Epilepsy Res. 2001;43:11–58. doi: 10.1016/S0920-1211(00)00171-6. [DOI] [PubMed] [Google Scholar]
- 8.Enington AC, Coyne L, Stohr T, Selve N, Lees G. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology. 2006;50:1016–1029. doi: 10.1016/j.neuropharm.2006.02.002. [DOI] [PubMed] [Google Scholar]
- 9.Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci. 2004;5:553–564. doi: 10.1038/nrn1430. [DOI] [PubMed] [Google Scholar]
- 10.Stoehr T, Lees G, Enington A, et al. Lacosamide has a dual mode of action: selective enhancement of sodium channel slow inactivation and modulation of CRMP-2. Presented at the 9th International Conference on the Mechanisms and Treatment of Neuropathic Pain; November 4, 2005; Bermuda.
- 11.Czech T, Yang JW, Csaszar E, Kappler J, Baumgartner C, Lubec G. Reduction of hippocampal collapsin response mediated protein-2 in patients with mesial temporal lobe epilepsy. Neurochem Res. 2004;29:2189–2196. doi: 10.1007/s11064-004-7025-3. [DOI] [PubMed] [Google Scholar]
- 12.Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A, Kaibuchi K. GSK-3β regulates phosphorylation of CRMP-2 and neuronal polarity. Cell. 2005;120:137–149. doi: 10.1016/j.cell.2004.11.012. [DOI] [PubMed] [Google Scholar]
- 13.Cawello W, Kropeit D, Schiltmeyer B, Hammes W, Horstmann R. Food does not affect the pharmacokinetics of SPM 927. Epilepsia. 2004;45(suppl 7):307–307. [Google Scholar]
- 14.Kropeit D, Schiltmeyer B, Cawello W, Hammes W, Horstmann R. Bioequivalence of short-time infusions compared to oral administration of SPM 927. Epilepsia. 2004;45(suppl 7):123–124. [Google Scholar]
- 15.Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI) Epilepsy Res. 2002;51:31–71. doi: 10.1016/S0920-1211(02)00106-7. [DOI] [PubMed] [Google Scholar]
- 16.Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII) Epilepsy Res. 2004;61:1–48. doi: 10.1016/j.eplepsyres.2004.07.010. [DOI] [PubMed] [Google Scholar]
- 17.Horstmann R, Bonn R, Cawello W, Doty P, Rudd D. Basic clinical pharmacological investigations of the new antiepileptic drug SPM 927. Epilepsia. 2002;43(suppl 7):188–188. [Google Scholar]
- 18.Schiltmeyer B, Cawello W, Kropeit D, Hammes W, Horstmann R. Pharmacokinetics of the new antiepileptic drug SPM 927 in human subjects with different age and gender. Epilepsia. 2004;45(suppl 7):313–313. [Google Scholar]
- 19.Kropeit D, Koch B, Schiltmeyer B, Cawello W, Horstmann R, Scharfenecker U. Low drug-interaction potential of lacosamide. J Pain. 2005;6(suppl 1):S34–S34. [Google Scholar]
- 20.Horstmann R, Bonn R, Cawello W, Doty P, Rudd D. SPM 927 does not interact with valproic acid and carbamazepine. Epilepsia. 2003;44(suppl 9):97–97. [Google Scholar]
- 21.Kropeit D, Scharfenecker U, Schiltmeyer B, et al. Lacosamide has low potential for drug-drug interaction. Presented at the 59th Annual Meeting of the American Epilepsy Society; December 2, 2005; Washington, DC.
- 22.Jatuzis D, Biton V, Ben-Menachem E, Abou-Khalil B, Doty P, Rudd GD. Evaluation of the effect of oral lacosamide on concomitant AED plasma concentrations in patients with partial seizures. Epilepsia. 2005;46(suppl 8):170–170. [Google Scholar]
- 23.Fountain NB, French JA, Privitera MD. Harkoseride: safety and tolerability of a new antiepileptic drug in patients with refractory partial seizures. Epilepsia. 2000;41(suppl 7):169–169. [Google Scholar]
- 24.Sachdeo R, Montouris G, Beydoun A, et al. An open-label, maximum tolerated dose trial to evaluate oral SPM 927 as adjunctive therapy in patients with partial seizures. Neurology. 2003;60(suppl 1):A433–A433. [Google Scholar]
- 25.Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of adjunctive oral lacosamide for the treatment of partial-onset seizures in patients with epilepsy. Neurology. 2005;64(suppl 1):A187–A187. [Google Scholar]
- 26.Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, Sullivan T. Lacosamide: efficacy and safety as oral adjunctive therapy in adults with partial seizures. Epilepsia. 2006;47(suppl 4):3–3. doi: 10.1111/j.1528-1167.2008.01951.x. [DOI] [PubMed] [Google Scholar]
- 27.Biton V, Rosenfeld W, Fountain NB, Vaiciene N, Whitesides J, Sommerville K. Safety, tolerability, and pharmacokinetics of intravenous lacosamide as replacement for oral lacosamide in subjects with partial seizures. Neurology. 2005;64(suppl 1):A119–A119. [Google Scholar]
- 28.Tatum WO, Galvez R, Benbadis S, Carrazana E. New antiepileptic drugs: into the new millennium. Arch Fam Med. 2000;9:1135–1141. doi: 10.1001/archfami.9.10.1135. [DOI] [PubMed] [Google Scholar]